{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:54:18Z","timestamp":1790380458009,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2017.10.075","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T06:19:30Z","timestamp":1509517170000},"page":"7346-7354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["National Institute of Allergy and Infectious Diseases workshop report: \u201cChlamydia vaccines: The way forward\u201d"],"prefix":"10.1016","volume":"37","author":[{"given":"Guangming","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Brunham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"de la Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Darville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2017.10.075_b0005","doi-asserted-by":"crossref","first-page":"e0143304","DOI":"10.1371\/journal.pone.0143304","article-title":"Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting","volume":"10","author":"Newman","year":"2015","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2017.10.075_b0010","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1086\/652395","article-title":"Risk of sequelae after Chlamydia trachomatis genital infection in women","volume":"201","author":"Haggerty","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.10.075_b0015","unstructured":"CDC. Chlamydia screening percentages reported by commercial and medicaid plans by state and year; 2014. <https:\/\/www.cdc.gov\/std\/chlamydia\/chlamydia-screening-2014.htm> [cited 2016 December 13]. Available from: <https:\/\/www.cdc.gov\/std\/chlamydia\/chlamydia-screening-2014.htm>."},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0020","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3201\/eid2106.141270","article-title":"Cost-effectiveness of Chlamydia vaccination programs for young women","volume":"21","author":"Owusu-Edusei","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"21","key":"10.1016\/j.vaccine.2017.10.075_b0025","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra1411426","article-title":"Pelvic inflammatory disease","volume":"372","author":"Brunham","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.075_b0030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/infdis\/jiw178","article-title":"Proportion of pelvic inflammatory disease cases caused by Chlamydia trachomatis: consistent picture from different methods","volume":"214","author":"Price","year":"2016","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.075_b0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1148\/radiology.210.1.r99ja04209","article-title":"MR imaging in pelvic inflammatory disease: comparison with laparoscopy and US","volume":"210","author":"Tukeva","year":"1999","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.075_b0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/OLQ.0000000000000533","article-title":"Whole-exome sequencing to identify novel biological pathways associated with infertility after pelvic inflammatory disease","volume":"44","author":"Taylor","year":"2017","journal-title":"Sex Transm Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.075_b0045","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.4049\/jimmunol.1001240","article-title":"A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans","volume":"185","author":"Wang","year":"2010","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.075_b0050","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/AOG.0b013e3182519326","article-title":"Chlamydia trachomatis antigens recognized in women with tubal factor infertility, normal fertility, and acute infection","volume":"119","author":"Budrys","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.075_b0055","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.fertnstert.2011.06.021","article-title":"Genome-wide identification of Chlamydia trachomatis antigens associated with tubal factor infertility","volume":"96","author":"Rodgers","year":"2011","journal-title":"Fertil Steril"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.075_b0060","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/infdis\/jiw485","article-title":"Identification of Chlamydia trachomatis antigens recognized by T cells from highly exposed women who limit or resist genital tract infection","volume":"214","author":"Russell","year":"2016","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.075_b0065","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/infdis\/jiv438","article-title":"Analysis of factors driving incident and ascending infection and the role of serum antibody in Chlamydia trachomatis genital tract infection","volume":"213","author":"Russell","year":"2016","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0070","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1128\/IAI.00154-15","article-title":"Chlamydia muridarum induction of glandular duct dilation in mice","volume":"83","author":"Sun","year":"2015","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.075_b0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.olq.0000148299.14513.11","article-title":"Histopathologic changes related to fibrotic oviduct occlusion after genital tract infection of mice with Chlamydia muridarum","volume":"32","author":"Shah","year":"2005","journal-title":"Sex Transm Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.075_b0080","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1128\/IAI.01543-13","article-title":"Reduced live organism recovery and lack of hydrosalpinx in mice infected with plasmid-free Chlamydia muridarum","volume":"82","author":"Lei","year":"2014","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0085","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1128\/IAI.70.6.2741-2751.2002","article-title":"Immunity to murine chlamydial genital infection","volume":"70","author":"Morrison","year":"2002","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.075_b0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tim.2016.09.006","article-title":"Chlamydial plasmid-dependent pathogenicity","volume":"25","author":"Zhong","year":"2017","journal-title":"Trends Microbiol"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.075_b0095","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1128\/IAI.02576-14","article-title":"Plasmid-encoded Pgp3 is a major virulence factor for Chlamydia muridarum to induce hydrosalpinx in mice","volume":"82","author":"Liu","year":"2014","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.075_b0100","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1128\/IAI.00746-15","article-title":"Chlamydial plasmid-encoded virulence factor Pgp3 neutralizes the antichlamydial activity of human cathelicidin LL-37","volume":"83","author":"Hou","year":"2015","journal-title":"Infect Immun"},{"issue":"30","key":"10.1016\/j.vaccine.2017.10.075_b0105","doi-asserted-by":"crossref","first-page":"22068","DOI":"10.1074\/jbc.M113.475012","article-title":"Structure of the Chlamydia trachomatis immunodominant antigen Pgp3","volume":"288","author":"Galaleldeen","year":"2013","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.vaccine.2017.10.075_b0110","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1128\/IAI.00386-10","article-title":"Frameshift mutations in a single novel virulence factor alter the in vivo pathogenicity of Chlamydia trachomatis for the female murine genital tract","volume":"78","author":"Sturdevant","year":"2010","journal-title":"Infect Immun"},{"issue":"32","key":"10.1016\/j.vaccine.2017.10.075_b0115","doi-asserted-by":"crossref","first-page":"12069","DOI":"10.1073\/pnas.0603866103","article-title":"Monitoring the T cell response to genital tract infection","volume":"103","author":"Roan","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2017.10.075_b0120","doi-asserted-by":"crossref","first-page":"A133","DOI":"10.1136\/sextrans-2015-052270.350","article-title":"Pathogenicity of plasmid positive and negative Chlamydia trachomatis in a macaque model of ocular and genital tract diseases","volume":"91","author":"Patton","year":"2015","journal-title":"Sex Transm Infect"},{"issue":"10","key":"10.1016\/j.vaccine.2017.10.075_b0125","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1128\/IAI.00841-15","article-title":"Comparable genital tract infection, pathology, and immunity in rhesus macaques inoculated with wild-type or plasmid-deficient Chlamydia trachomatis serovar D","volume":"83","author":"Qu","year":"2015","journal-title":"Infect Immun"},{"issue":"9379","key":"10.1016\/j.vaccine.2017.10.075_b0130","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0140-6736(03)13909-8","article-title":"Strategies for control of trachoma: observational study with quantitative PCR","volume":"362","author":"Solomon","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.075_b0135","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1371\/journal.pntd.0000341","article-title":"The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up","volume":"2","author":"Grassly","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.075_b0140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1128\/IAI.63.2.389-392.1995","article-title":"Subjects recovering from human ocular chlamydial infection have enhanced lymphoproliferative responses to chlamydial antigens compared with those of persistently diseased controls","volume":"63","author":"Bailey","year":"1995","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.075_b0145","first-page":"699","article-title":"Trachoma vaccine field trials in The Gambia","volume":"67","author":"Sowa","year":"1969","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2017.10.075_b0150","doi-asserted-by":"crossref","first-page":"791847","DOI":"10.1155\/2015\/791847","article-title":"Trachoma and ocular chlamydial infection in the era of genomics","volume":"2015","author":"Derrick","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.vaccine.2017.10.075_b0155","unstructured":"Bailey RL, Burton MJ, Mabey D. Trachoma vaccine trials in the Gambia. In: Schachter J, Byrne G, Chernesky M, editors. Asilomar conference grounds, Pacific Grove, Calif, USA; 2014. p. 485\u20138."},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.075_b0160","doi-asserted-by":"crossref","first-page":"723","DOI":"10.4269\/ajtmh.1969.18.723","article-title":"Studies on trachoma. VI. Microbiological observations in a field trial in Saudi Arabia of bivalent rachoma vaccine at three dosage levels","volume":"18","author":"Nichols","year":"1969","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.10.075_b0165","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3181\/00379727-112-28112","article-title":"Field studies of protection from infection by experimental trachoma virus vaccine in preschool-aged children on Taiwan","volume":"112","author":"Grayston","year":"1963","journal-title":"Proc Soc Exp Biol Med"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.075_b0170","doi-asserted-by":"crossref","first-page":"Suppl:1645","DOI":"10.1016\/0002-9394(67)94158-X","article-title":"Field trial of a monovalent and of a bivalent mineral oil adjuvant trachoma vaccine in Taiwan school children","volume":"63","author":"Woolridge","year":"1967","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.075_b0175","doi-asserted-by":"crossref","first-page":"Suppl:1650","DOI":"10.1016\/0002-9394(67)94159-1","article-title":"Long-term follow-up of the initial (1959-1960) trachoma vaccine field trial on Taiwan","volume":"63","author":"Woolridge","year":"1967","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.075_b0180","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/sj.gene.6364384","article-title":"Genetic variation at the TNF locus and the risk of severe sequelae of ocular Chlamydia trachomatis infection in Gambians","volume":"8","author":"Natividad","year":"2007","journal-title":"Genes Immun"},{"issue":"9628","key":"10.1016\/j.vaccine.2017.10.075_b0185","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(08)60836-3","article-title":"Trachoma","volume":"371","author":"Wright","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.075_b0190","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJM197802232980805","article-title":"Chlamydial infections (first of three parts)","volume":"298","author":"Schachter","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.10.075_b0195","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1084\/jem.115.5.1009","article-title":"The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers","volume":"115","author":"Grayston","year":"1962","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.075_b0200","doi-asserted-by":"crossref","first-page":"Suppl:1133","DOI":"10.1016\/0002-9394(67)94095-0","article-title":"Pannus with experimental trachoma and inclusion conjunctivitis agent infection of Taiwan monkeys","volume":"63","author":"Wang","year":"1967","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.075_b0205","doi-asserted-by":"crossref","first-page":"639","DOI":"10.4269\/ajtmh.1966.15.639","article-title":"Studies on trachoma. V. Clinical observations in a field trial of bivalent trachoma vaccine at three dosage levels in Saudi Arabia","volume":"15","author":"Nichols","year":"1966","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"10.1016\/j.vaccine.2017.10.075_b0210","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1128\/IAI.00844-10","article-title":"Human conjunctival transcriptome analysis reveals the prominence of innate defense in Chlamydia trachomatis infection","volume":"78","author":"Natividad","year":"2010","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.075_b0215","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1128\/IAI.05718-11","article-title":"Active trachoma is associated with increased conjunctival expression of IL17A and profibrotic cytokines","volume":"79","author":"Burton","year":"2011","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.075_b0220","doi-asserted-by":"crossref","first-page":"e0003763","DOI":"10.1371\/journal.pntd.0003763","article-title":"Pathogenesis of progressive scarring trachoma in Ethiopia and Tanzania and its implications for disease control: two cohort studies","volume":"9","author":"Burton","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.075_b0225","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1128\/IAI.05965-11","article-title":"Innate immune responses and modified extracellular matrix regulation characterize bacterial infection and cellular\/connective tissue changes in scarring trachoma","volume":"80","author":"Hu","year":"2012","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0230","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1128\/IAI.65.6.2145-2152.1997","article-title":"Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice","volume":"65","author":"Cotter","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.10.075_b0235","series-title":"The role of T cell subpopulations in resolution of chlamydial genital infection of mice. Chlamydial infections","first-page":"241","author":"Ramsey","year":"1990"},{"issue":"10","key":"10.1016\/j.vaccine.2017.10.075_b0240","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/IAI.60.10.4427-4429.1992","article-title":"Effect of gamma interferon on resolution of murine chlamydial genital infection","volume":"60","author":"Rank","year":"1992","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.075_b0245","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1128\/IAI.63.12.4661-4668.1995","article-title":"Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection","volume":"63","author":"Morrison","year":"1995","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.075_b0250","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1128\/IAI.68.12.6979-6987.2000","article-title":"Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells","volume":"68","author":"Morrison","year":"2000","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.075_b0255","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1128\/IAI.39.1.463-465.1983","article-title":"Humoral immune response in acquired immunity to chlamydial genital infection of female guinea pigs","volume":"39","author":"Rank","year":"1983","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.075_b0260","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1128\/IAI.69.4.2643-2649.2001","article-title":"Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells","volume":"69","author":"Morrison","year":"2001","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2017.10.075_b0265","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1128\/IAI.00622-10","article-title":"CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection","volume":"78","author":"Farris","year":"2010","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2017.10.075_b0270","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1128\/IAI.00491-09","article-title":"Chlamydia muridarum-specific CD4 T-cell clones recognize infected reproductive tract epithelial cells in an interferon-dependent fashion","volume":"77","author":"Jayarapu","year":"2009","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2017.10.075_b0275","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.4049\/jimmunol.1002596","article-title":"Chlamydia-specific CD4 T cell clones control Chlamydia muridarum replication in epithelial cells by nitric oxide-dependent and -independent mechanisms","volume":"185","author":"Jayarapu","year":"2010","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.075_b0280","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.4049\/jimmunol.1102764","article-title":"Plac8-dependent and inducible NO synthase-dependent mechanisms clear Chlamydia muridarum infections from the genital tract","volume":"188","author":"Johnson","year":"2012","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.075_b0285","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/jir.1986.6.389","article-title":"Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity","volume":"6","author":"Byrne","year":"1986","journal-title":"J Interferon Res"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.075_b0290","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1128\/IAI.53.2.347-351.1986","article-title":"Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells","volume":"53","author":"Byrne","year":"1986","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2017.10.075_b0295","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1073\/pnas.90.9.3998","article-title":"Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro","volume":"90","author":"Beatty","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.075_b0300","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.4049\/jimmunol.179.3.1814","article-title":"The p47 GTPases Iigp2 and Irgb10 regulate innate immunity and inflammation to murine Chlamydia psittaci infection","volume":"179","author":"Miyairi","year":"2007","journal-title":"J Immunol"},{"issue":"30","key":"10.1016\/j.vaccine.2017.10.075_b0305","doi-asserted-by":"crossref","first-page":"10658","DOI":"10.1073\/pnas.0504198102","article-title":"Chlamydial IFN-gamma immune evasion is linked to host infection tropism","volume":"102","author":"Nelson","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"38","key":"10.1016\/j.vaccine.2017.10.075_b0310","doi-asserted-by":"crossref","first-page":"14092","DOI":"10.1073\/pnas.0603338103","article-title":"The p47 GTPases Igtp and Irgb10 map to the Chlamydia trachomatis susceptibility locus Ctrq-3 and mediate cellular resistance in mice","volume":"103","author":"Bernstein-Hanley","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.075_b0315","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mib.2006.12.003","article-title":"Chlamydial interferon gamma immune evasion influences infection tropism","volume":"10","author":"McClarty","year":"2007","journal-title":"Curr Opin Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.075_b0320","doi-asserted-by":"crossref","first-page":"e0124840","DOI":"10.1371\/journal.pone.0124840","article-title":"Plasmid-encoded Pgp5 is a significant contributor to Chlamydia muridarum induction of hydrosalpinx","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.075_b0325","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/IAI.03158-14","article-title":"In vitro passage selects for Chlamydia muridarum with enhanced infectivity in cultured cells but attenuated pathogenicity in mouse upper genital tract","volume":"83","author":"Chen","year":"2015","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.075_b0330","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1128\/IAI.01171-15","article-title":"The chromosome-encoded hypothetical protein TC0668 is an upper genital tract pathogenicity factor of Chlamydia muridarum","volume":"84","author":"Conrad","year":"2015","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0335","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.4049\/jimmunol.179.6.4027","article-title":"Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease","volume":"179","author":"O'Connell","year":"2007","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0340","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.4049\/jimmunol.1002952","article-title":"Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells","volume":"186","author":"Yu","year":"2011","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.075_b0345","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.micinf.2013.02.001","article-title":"Induction of protective immunity against Chlamydia muridarum intravaginal infection with the chlamydial immunodominant antigen macrophage infectivity potentiator","volume":"15","author":"Lu","year":"2013","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2017.10.075_b0350","unstructured":"Stary G, Olive A, Radovic-Moreno AF, Gondek D, Alvarez D, Basto PA, et al. VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science 2015;348(6241):aaa8205. doi: 10.1126\/science.aaa8205. PubMed PMID: 26089520; PubMed Central PMCID: PMCPMC4605428."},{"issue":"10","key":"10.1016\/j.vaccine.2017.10.075_b0355","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1586\/erv.09.98","article-title":"Chlamydia vaccine candidates and tools for chlamydial antigen discovery","volume":"8","author":"Rockey","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.10.075_b0360","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/978-1-4939-3387-7_23","article-title":"Using MHC molecules to define a Chlamydia T cell vaccine","volume":"1403","author":"Karunakaran","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"36","key":"10.1016\/j.vaccine.2017.10.075_b0365","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1016\/j.vaccine.2014.06.002","article-title":"Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice","volume":"32","author":"Yu","year":"2014","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.075_b0370","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1084\/jem.193.8.935","article-title":"Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors","volume":"193","author":"Zhong","year":"2001","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0375","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1128\/IAI.00275-15","article-title":"Characterization of CPAF critical residues and secretion during Chlamydia trachomatis infection","volume":"83","author":"Yang","year":"2015","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2017.10.075_b0380","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1128\/IAI.72.7.3869-3875.2004","article-title":"Intramolecular dimerization is required for the chlamydia-secreted protease CPAF to degrade host transcriptional factors","volume":"72","author":"Dong","year":"2004","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0385","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chom.2008.10.005","article-title":"Structural basis for activation and inhibition of the secreted chlamydia protease CPAF","volume":"4","author":"Huang","year":"2008","journal-title":"Cell Host Microbe"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.075_b0390","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1128\/IAI.72.12.7164-7171.2004","article-title":"Human antibody responses to a Chlamydia-secreted protease factor","volume":"72","author":"Sharma","year":"2004","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2017.10.075_b0395","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1128\/IAI.00280-16","article-title":"The chlamydia-secreted protease CPAF promotes chlamydial survival in the mouse lower genital tract","volume":"84","author":"Yang","year":"2016","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2017.10.075_b0400","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.micinf.2016.07.002","article-title":"Neutralizing antichlamydial activity of complement by chlamydia-secreted protease CPAF","volume":"18","author":"Yang","year":"2016","journal-title":"Microbes Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0405","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.micinf.2015.02.005","article-title":"Chlamydia-secreted protease CPAF degrades host antimicrobial peptides","volume":"17","author":"Tang","year":"2015","journal-title":"Microbes Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.075_b0410","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.1128\/IAI.01119-06","article-title":"Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele","volume":"74","author":"Murthy","year":"2006","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2017.10.075_b0415","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/IAI.00346-10","article-title":"Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge","volume":"78","author":"Li","year":"2010","journal-title":"Infect Immun"},{"issue":"14","key":"10.1016\/j.vaccine.2017.10.075_b0420","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.vaccine.2011.01.074","article-title":"Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge","volume":"29","author":"Murthy","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.075_b0425","article-title":"Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs","author":"Wali","year":"2016","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.075_b0430","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1084\/jem.167.3.817","article-title":"High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis","volume":"167","author":"Stephens","year":"1988","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.075_b0435","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1128\/IAI.58.5.1450-1455.1990","article-title":"Mapping antigenic sites on the major outer membrane protein of Chlamydia trachomatis with synthetic peptides","volume":"58","author":"Zhong","year":"1990","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.075_b0440","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1084\/jem.172.1.203","article-title":"Identification and characterization of T helper cell epitopes of the major outer membrane protein of Chlamydia trachomatis","volume":"172","author":"Su","year":"1990","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.075_b0445","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1128\/IAI.38.2.745-754.1982","article-title":"Neutralization of Chlamydia trachomatis infectivity with antibodies to the major outer membrane protein","volume":"38","author":"Caldwell","year":"1982","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2017.10.075_b0450","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.4049\/jimmunol.151.7.3728","article-title":"Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for Chlamydia trachomatis","volume":"151","author":"Zhong","year":"1993","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.075_b0455","doi-asserted-by":"crossref","first-page":"674","DOI":"10.4049\/jimmunol.147.2.674","article-title":"A single peptide from the major outer membrane protein of Chlamydia trachomatis elicits T cell help for the production of antibodies to protective determinants","volume":"147","author":"Allen","year":"1991","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.075_b0460","doi-asserted-by":"crossref","first-page":"8153","DOI":"10.1128\/IAI.73.12.8153-8160.2005","article-title":"Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria","volume":"73","author":"Pal","year":"2005","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0465","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.vaccine.2005.08.074","article-title":"Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge","volume":"24","author":"Pal","year":"2006","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2017.10.075_b0470","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.4049\/jimmunol.1303392","article-title":"Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum","volume":"192","author":"Tifrea","year":"2014","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.075_b0475","doi-asserted-by":"crossref","first-page":"8063","DOI":"10.4049\/jimmunol.0804375","article-title":"Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine","volume":"182","author":"Kari","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.075_b0480","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/icb.2015.79","article-title":"A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-gamma(+) CMI responses protects against a genital infection in minipigs","volume":"94","author":"Boje","year":"2016","journal-title":"Immunol Cell Biol"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0485","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/infdis\/jiv137","article-title":"Protection against Chlamydia trachomatis infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein","volume":"212","author":"Olsen","year":"2015","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.075_b0490","doi-asserted-by":"crossref","first-page":"e32997","DOI":"10.1371\/journal.pone.0032997","article-title":"Induction of protective immunity against Chlamydia muridarum intravaginal infection with a chlamydial glycogen phosphorylase","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2017.10.075_b0495","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0264-410X(02)00631-X","article-title":"DNA immunization with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower to the upper genital tract in C3H\/HeN mice","volume":"21","author":"Donati","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.075_b0500","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1186\/s12865-014-0056-x","article-title":"Vibrio cholerae ghosts (VCG) exert immunomodulatory effect on dendritic cells for enhanced antigen presentation and induction of protective immunity","volume":"15","author":"Eko","year":"2014","journal-title":"BMC Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.075_b0505","first-page":"188","article-title":"Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine","volume":"40","author":"Ifere","year":"2007","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0510","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.cell.2016.08.005","article-title":"Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies","volume":"166","author":"Briney","year":"2016","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.075_b0515","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1128\/IAI.06339-11","article-title":"PmpG303-311, a protective vaccine epitope that elicits persistent cellular immune responses in Chlamydia muridarum-immune mice","volume":"80","author":"Johnson","year":"2012","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T20:50:53Z","timestamp":1693169453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17314834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":103,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X17314834"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National Institute of Allergy and Infectious Diseases workshop report: \u201cChlamydia vaccines: The way forward\u201d","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}